Androsterone.

DHEA sits upstream in the same steroidogenic sequence, converting through androstenedione and 5-alpha reduction to androsterone. The two occupy adjacent points on one pathway.

Androsterone is formed from androstenedione by 5-alpha reduction followed by 3-alpha-hydroxysteroid dehydrogenase. Supplying both loads the same conversion sequence at two points.

Androstenediol feeds the same androgen pool through 3-beta-hydroxysteroid dehydrogenase. Its metabolites converge on the same 5-alpha-reduced products.

Saw palmetto fatty acids inhibit 5-alpha-reductase, the enzyme that generates 5-alpha-reduced steroids such as androsterone. Running them together works against the formation step.

Androsterone is cleared largely as its glucuronide, and glucarate inhibits the gut beta-glucuronidase that would otherwise free the steroid from that conjugate. The pairing changes how much is returned to circulation.

Zinc is required by several steroid-metabolising enzymes including aromatase and the hydroxysteroid dehydrogenases. Its status influences the balance between androgen and estrogen products.

The hydroxysteroid dehydrogenases that interconvert androsterone with its 3-alpha-hydroxy and 17-keto partners run on NAD+ and NADH as the hydride carrier. Which direction the enzyme favours tracks the cellular NAD+ to NADH ratio, not the steroid concentration. Nicotinamide pool status therefore sits upstream of how androsterone is handled.

Nicotinamide riboside feeds the salvage route into the NAD pool that hydroxysteroid dehydrogenases draw on. The link to androsterone is one step removed: it supplies the cofactor rather than acting on the steroid. Human supplement work has measured NAD pool changes, not steroid handling, so this is mechanistic reasoning and not an outcome.

Niacin is a dietary precursor of NAD, the cofactor for the reductive and oxidative steps around the androstane 17-ketosteroids. Adequacy matters more than extra intake here, since the pathway is cofactor-dependent rather than cofactor-driven.

Androsterone leaves the body mainly as a sulfate or glucuronide conjugate. The sulfate arm needs PAPS, and the sulfate for PAPS comes largely from cysteine oxidation. A thin cysteine and inorganic sulfate pool constrains sulfation capacity across all steroid substrates competing for it.

Methionine sits upstream of cysteine through transsulfuration, so it indirectly supplies the sulfate used to conjugate 17-ketosteroids. The connection is two enzymatic steps away from androsterone itself. No human study has measured methionine intake against androsterone conjugation.

Sulfite oxidase, the molybdenum-dependent step, converts sulfite to the inorganic sulfate that feeds PAPS. That places molybdenum quietly behind steroid sulfation capacity. It is a permissive cofactor role, not a way to push conjugation faster.

Silymarin constituents inhibit UDP-glucuronosyltransferase and sulfotransferase isoforms in isolated systems, the same conjugating families that clear androstane 17-ketosteroids. Slower conjugation would mean a longer unconjugated residence time. The evidence is enzyme-level and in vitro, not a measured change in human steroid profiles.

Short boron supplementation studies in adults have reported shifts in circulating androgen and sex-hormone-binding-globulin measures. Those are blood markers, not clinical outcomes, and androsterone was generally not the analyte measured. The plausible link is a shift in the upstream androgen pool that androsterone is metabolised from.

DIM alters the balance of hepatic phase I hydroxylation of steroid substrates in preclinical systems. A shift in hydroxylation balance changes which metabolites dominate the excreted steroid profile, and urinary androsterone is part of that profile. This is preclinical enzyme reasoning, not human data on androsterone itself.

Plant sterols including beta-sitosterol have been reported to interact with 5-alpha-reductase in isolated systems. Androsterone sits downstream of a 5-alpha reduction step, so reduced flux through that enzyme would in principle change how much is formed. In vitro only, and human steroid-profile confirmation is absent.

Glycyrrhizin and its aglycone inhibit steroidogenic hydroxysteroid dehydrogenase steps, and small human studies have reported lower circulating androgen markers during licorice intake. That points in the opposite direction to an androgen-metabolite supplement, which is why it is worth flagging rather than hiding. Markers again, and small samples.

Ashwagandha trials have measured changes in circulating androgen and cortisol markers in adults. Anything that moves the upstream androgen pool moves the pool androsterone is derived from. The trials measured hormone markers, not androsterone or its urinary conjugates.

Small trials of Eurycoma longifolia report shifts in androgen and binding-globulin markers. The overlap with androsterone is at the level of the shared upstream steroid pool. Sample sizes are small and preparations vary between studies, so the strength here is low.

Vitamin D and the androstane steroids both derive from cholesterol, and vitamin D status has been associated with androgen markers in observational cohorts. The shared precursor is established chemistry; the marker association is not causal. No work connects vitamin D intake to androsterone specifically.

Grape seed procyanidins inhibit aromatase in cell systems, which changes the split between androgenic and estrogenic metabolites of a shared precursor pool. Androsterone is a downstream 17-ketosteroid of that same pool. Cell-level evidence only.